Antimyeloperoxidase (MPO) Antibodies
Also known as: p-ANCA-Specific Antibodies
Use
Antibodies against myeloperoxidase (MPO) are referred to as p-ANCA subtype, since they form a perinuclear fluorescence pattern. This ANCA-fluorescent (antineutrophil cytoplasmic antibodies) subtype includes other antibodies such as antibodies against lactoferrin, cathepsin G or elastase. However, in at least 60% of p-ANCA reactivity cases, the main antigen is MPO. Anti-MPO antibodies are primarily considered an important indicator for progressing nephritis; they are largely present in patients with severe renal impairment. They are also important for diagnosing Churg-Strauss syndrome and microscopic polyangiitis. The presence or absence of antibodies against MPO and PR3 in combination with the positivity of antinuclear antibodies may be regarded as a differentiating marker between ANCA-associated vasculitis and SLE-induced vasculitis.
Special Instructions
Not provided.
Limitations
The test may not detect all forms of MPO antibodies, and cross-reactivity with other antibodies such as lactoferrin, cathepsin G, or elastase can occur, potentially affecting specificity. The results should be interpreted in conjunction with clinical findings and other laboratory tests. In some cases, additional time for confirmatory or reflex tests might be necessary, affecting overall turnaround time.
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 46266-3
- 46266-3
Result Turnaround Time
2-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.6 mL
Minimum Volume
0.3 mL
Container
Red-top tube or gel-barrier tube
Storage Instructions
Room temperature
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |
